Jing-Mei Yu

A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.

Yicheng Zhao, Xin-Ning Qu, Jing Lan, 2022, International immunopharmacology.